Sign in
Stories
Certis Oncology Secures $10 Million in Funding
Share
AI Cancer Diagnostics Collaboration
AI Partnerships Drive Drug Discovery
AI Revolutionizes Toxicologic Pathology ...
AGO Recognition Boosts BluePrint® Impact
BenevolentAI's Shareholder Letter 2023
Bioptimus Launches AI Startup for Biotec...
Overview
API
Certis Oncology Solutions successfully closed a $10 million Series C funding round, bringing total funds raised to $42 million. The company appointed John R. Tozzi as Chairman of its Board of Directors. Certis aims to advance cancer research through advanced tumor models, AI-based intellectual property, and specialized contract research services.
Ask a question
How does Certis Oncology's focus on AI-based intellectual property contribute to the advancement of cancer research?
How might the funding impact the development and commercialization of advanced tumor models in cancer research?
What potential implications does the appointment of John R. Tozzi as Chairman of the Board of Directors have on the company's future direction?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Oct 2023
Nov 2023
Dec 2023
Coverage